Colossal closes $150M Series B with eye on the iconic dodo
Tuesday, de-extinction company Colossal Biosciences closed a mammoth, $150 million Series B financing round and announced plans to resurrect the iconic Dodo – extinct since the 17th century.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
uniQure gains rights to Apic’s gene therapy for SOD1-ALS
/in Business, Clinical Trials, R&DuniQure inked a deal with Apic Bio Tuesday to gain development and commercialization rights for APB-102, a therapeutic intended to treat a rare, genetic form of ALS.
U.S. to end COVID-19 emergency declarations on May 11
/in Business, FDA/Regulatory, Health, TherapeuticsPresident Joe Biden’s administration on Monday said it will end COVID-19 emergency declarations on May 11, nearly three years after the United States imposed sweeping pandemic measures to curb the spread of the illness.
Bayer under investor pressure to speed up CEO changeover
/in Business, TherapeuticsA top-10 shareholder in Bayer on Tuesday called on the group’s supervisory board to replace chief executive Werner Baumann quickly, adding to investor pressure to restore trust and revive the German drugmaker’s sagging share price.
Pfizer forecasts steep fall in 2023 sales of COVID products
/in Business, R&D, TherapeuticsPfizer Inc. on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment in 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories.
What will it take for AI to live up to its hype?
/in Business, R&DThe pharmaceutical industry is expected to spend more than $3 billion on artificial intelligence by 2025 – up from $463 million in 2019. AI clearly adds value, but advocates say it is not yet living up to its potential.
AbbVie’s Humira gets a U.S. rival, but costs could stay high
/in Business, FDA/Regulatory, R&D, TherapeuticsU.S. patients will finally get access to cheaper versions of AbbVie Inc.’s blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
U.S. seeks to expand birth control coverage under Obamacare
/in Health, TherapeuticsWomen whose employers have opted out of covering contraceptives under their health insurance plans on religious grounds would gain no-cost access to birth control under a rule proposed by the Biden administration on Monday.
FDA approves first reversible BTK inhibitor
/in Business, FDA, R&D, TherapeuticsThe FDA granted Eli Lilly’s Jaypirca (pirtobrutinib) accelerated approval for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL), the company announced Friday.
Amgen downsizes by 300 amid industry constriction
/in Business, R&D, TherapeuticsAmgen is implementing organizational changes that include laying off approximately 300 team members to “better manage against industry headwinds,” a company spokesperson confirmed to BioSpace via email Monday.